ArticleClinical case reports2026
Primary Small Cell Neuroendocrine Carcinoma of the Sublingual Gland Treated With Definitive Chemoradiotherapy: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary sublingual gland small cell neuroendocrine carcinoma (SCNEC) is extremely rare, with only one prior case reported, and no site-specific standard of care has been established. We report a case of primary sublingual gland SCNEC treated with definitive concurrent chemoradiotherapy (CRT). A 69-year-old man presented with a 21 × 15-mm right sublingual mass showing fluorodeoxyglucose uptake (SUVmax 9.9) on PET/CT. No nodal or distant disease was found. Biopsy revealed small cell morphology positive for INSM1/synaptophysin and pan-cytokeratin, with a high Ki-67 index (> 95%). IMRT delivered 70 Gy in 35 fractions to the primary tumor with elective bilateral nodal irradiation (levels I-V, 46 Gy). Cisplatin (80 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.